Medical Unmet NeedsLEADING GLOBAL R&BD InnovatorCURACLE Co., Ltd. is introducing a new era,
welcoming 150 years of happiness and health, by developing
innovative new drugs with creative technology for incurable
diseases caused by the aging process and damage
to blood vessels.
New Challenge,
Miracle Cure,
Leading Global Market
- PRESENT
Unmet Medical Needs
-
Diabetic Retinopathy
-
Macular Degeneration
-
Ischemic Vascular Diseases
-
Diabetic Nephropathy
-
Cancer
-
NASH
-
Stroke
-
IBD
Inevitable Vascular Aging / Dysfunction
- KEY DEVELOPMENT
AREA

Vascular Diseases

Metabolic Diseases

/ Immunotherapy
- PRESENT
Creative Scientific
Finding
Innovative Molecules
New Clinical Concept
-
Vascular Normalization
-
Prevention of Aging
-
Restroation of Vascular Damage
-
Mitochondria Maintenance

present/future market
- FUTURE
Open Healthy
& Happy Living up
to 150 years old
Global growth by securing unparalleled
source technology and creating innovative new drugs
Strengthening market control through the continued success of the pipeline and global partnerships.
2019-2020Growth stage
Growth Stage– Candidate substance and early clinical phase portfolio
– Complete phase 2 clinical trial of CU01 / CU03
– Start clinical trial of CU06
– Start pre-clinical study of CU02 / CU04 / CU05
– Attract investment (Series B)
– Discover domestic and foreign partners
– Complete technical evaluation for special listings
– Complete phase 2 clinical trial of CU01 / CU03
– Start clinical trial of CU06
– Start pre-clinical study of CU02 / CU04 / CU05
– Attract investment (Series B)
– Discover domestic and foreign partners
– Complete technical evaluation for special listings
2021-2023Take-off stage
Take-off Stage –Initial public offering
–Pre-clinical and later-phase clinical portfolio
–L/O and co-development with domestic andforeign pharmaceutical companies
–Create milestone profits
–Establish second laboratory (toxicity/efficacy evaluation)
–Add new innovative pipeline
–Pre-clinical and later-phase clinical portfolio
–L/O and co-development with domestic andforeign pharmaceutical companies
–Create milestone profits
–Establish second laboratory (toxicity/efficacy evaluation)
–Add new innovative pipeline
2024 –Achieving VISION
Achieving VISION– Secure independent, innovative drug platform
– Launch independently developed global drugsGlobal Leading R&BD Innovator Focused
– Launch independently developed global drugs